TSE:AEZ - AEterna Zentaris Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
C$2.11 -0.09 (-4.09 %)
(As of 07/20/2018 04:00 PM ET)
Previous CloseC$2.20
Today's RangeC$2.11 - C$2.16
52-Week RangeC$1.10 - C$5.06
Volume1,000 shs
Average Volume12,504 shs
Market CapitalizationC$34.20 million
P/E RatioN/A
Dividend YieldN/A
Beta0.35
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women's health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others. The Company's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The Company focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The Company's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Receive AEZ News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZ and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange TSE
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolTSE:AEZ
CUSIPN/A
Phone+1-843-9003223

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-3,996.27%
Return on Equity-3,046.52%
Return on Assets-164.23%

Miscellaneous

EmployeesN/A
Outstanding Shares11,671,000
Market CapC$34.20

AEterna Zentaris (TSE:AEZ) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AEZ."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (TSE:AEZ) announced its quarterly earnings data on Monday, May, 7th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.12) by $1.22. The biopharmaceutical company earned $31.17 million during the quarter, compared to analyst estimates of $2.57 million. AEterna Zentaris had a negative net margin of 3,996.27% and a negative return on equity of 3,046.52%. View AEterna Zentaris' Earnings History.

When is AEterna Zentaris' next earnings date?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for AEterna Zentaris.

What is the consensus analysts' recommendation for AEterna Zentaris?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:
  • Carolyn Egbert, Independent Chairman of the Board
  • Michael Ward, President, Chief Executive Officer, Director
  • James Clavijo, Chief Financial Officer (Age 52)
  • Richard Sachse M.D. Ph.D., Senior Vice President, Chief Scientific Officer, Chief Medical Officer
  • Jude Dinges, Chief Commercial Officer, Senior Vice President (Age 58)
  • Eckhard G. Gunther Ph.D., Vice President - Alliance Management
  • Michael Teifel, Vice President - Non-Clinical Sciences
  • John W. Sharkey Ph.D., Business Development Consultant (Age 60)
  • Philip Allen Theodore, Corporate Secretary (Age 64)
  • David A. Dodd, Director (Age 65)

Has AEterna Zentaris been receiving favorable news coverage?

News headlines about AEZ stock have been trending somewhat positive on Saturday, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AEterna Zentaris earned a media sentiment score of 0.06 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 46.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of AEterna Zentaris?

Shares of AEZ and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEZ stock can currently be purchased for approximately C$2.11.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of C$34.20 million.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Dr Ste 302D, SUMMERVILLE, SC 29486-7790, United States. The biopharmaceutical company can be reached via phone at +1-843-9003223.


MarketBeat Community Rating for AEterna Zentaris (TSE AEZ)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.